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Abstract
Juvenile idiopathic arthritis (JIA) is a heterogeneous condition and therapeutic strategies vary in different JIA types.
The routinely accepted practice to start with Sulphasalazine (SS) as the first line treatment in patients with HLA B27
positive JIA proves to be ineffective in a large proportion of children.
Objective: to investigate HLA B27 positive JIA patients clinical characteristics, determined HLA B27 allele types and
their connection with antirheumatic treatment in homogenous patient groups.
Materials and methods: 56 patients diagnosed with JIA and observed over the period 2006 to 2009 included in
the study. HLAB27 allele types were determined using PCR method.
Results: In HLA B27 positive JIA patients mean disease onset was 12.34 ± 3.3 years. Most common (44%) JIA type
was enthesitis related arthritis. Positive response to the treatment with SS was found in 32% of patients,
Methotrexate (MTX) - in 43%, combined treatment - SS with MTX was effective in 12.5%. 12.5% of patients required
combination MTX with Enbrel.
Eight HLA B27 allele types were found in JIA patients in Latvia: *2702, *2703, *2704, *2705, *2710, *2715, *2717,
*2728. The most common was *2705 - in 55% of cases. Among all the patients enthesitis related arthritis most
commonly occurred in patients with HLAB*2705 allele (OR = 2.01, p < 0.02), oligoarthritis in patients with *2710
allele (OR = 3.0, p < 0.04) and polyarthritis with *2717 allele (OR = 3.0, p < 0.05). In patients with *2705 allele effec-
tive treatment was MTX (OR = 1.13, p < 0.03) and MTX with SS (OR = 2.02, p < 0.05), but in patients having *2703
allele - MTX with Enbrel (OR = 2.94, p < 0.02).
Conclusions: There are 8 different HLA B27 alleles in JIA patients in Latvia and the most common is *2705, but in
order to assert them to be disease associated alleles, more extensive studies are needed, including control group
of HLA B27 positive healthy individuals. Standard treatment approach with SS proves to be unsatisfactory in the
majority of JIA patients. To improve children’s quality of life achieving rapid disease control, the first line treatment
in HLA B27 positive patients should be MTX. In order to start with the most appropriate drug it is necessary to
determine HLAB 27 type at the onset of disease.
Introduction
Juvenile idiopathic arhtritis (JIA) is the most common
chronic rheumatic juvenile disease, causing substantial inva-
lidity, social and psychological problems both for the chil-
dren and their parents. According to information sources
the incidence of the disease is 1 - 22 per 100 000 children/
year and prevalence 8 - 150 per 100 000 children [1].
Nearly half of the patients continue carrying the disease
also in adult age [2]. Radiology tests have proved that bone
damages among most of the patients with systemic or poly-
articular arthritis, appear already within the first 2 years,
and among patients with oligoarthritis - within 5 years of
the disease. 50 - 70% of patients with systemic arthritis and
40 - 50% of patients with oligoarthritis in adult age, pre-
serve the disease in its active phase. 30 - 40% of patients
suffer from long-term joint dysfuncion , invalidity or physi-
cal incapacity, unemployment and 25 - 50% need surgical
help, including joint prosthetics [3]. JIA extra-articular
manifestations are uveitis, mainly iridocyclitis, which
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patients with polyarthritis. Complications of uveitis are
posterior sinechia, cataract, glaucoma and ocular disorders
[1]. During last 15 years, the tactics of medical care of JIA
patients has remarkably changed. The approach now is
early and aggressive, based on disease-modifying medica-
tion to suppress the inflammation promptly and effectively.
Thanks to this approach, the number of patients with func-
tional disability has considerably decreased.
J I Ai sn o tas i n g l ed i s e a s e ,b u tag r o u po fh e t e r o g e -
neous diseases that combines all kinds of chronic arthri-
tis of unknown aetiology, which persist more than 6
weeks and the onset is before 16 years of age. Heteroge-
neity of JIA becomes apparent in many ways: in the
onset of disease, in clinical features, symptoms, in the
progress of disease as well as in genetic basis.
According to ILAR (International League of Associa-
tions for Rheumatology) classification, JIA has 7 disease
types [4].
Up to now origin of the disease is unclear, pathogenesis
mechanism of the disease is still under research, but what
matters are environmental factors (psychological stress,
traumas, injuries, viral and bacterial infections) as well as
different genes, which determine a person’s characteristic
respondent (counter-action) features to immunity and
inflammation. Several studies have proved the importance
of certain genes being a risk factor in the development of
the disease. One of the most investigated genetic associa-
tions with certain rheumatic diseases is HLA alleles, which
were first described already in 1973, when it was proved
that there is an association between HLA B27 allele and
ankylosing spondylitis (AS) among adults [5,6]. Approxi-
mately 95% of AS patients carry HLA B27, at the same
time in general population this allele is present only in
10% of European inhabitants, 1% in Japan, and the greatest
occurrence is among native Americans (10 - 50%) [5,7]. It
is documented that JIA with oligoarthritis has a positive
association with several HLA class I un II gene alleles:
HLA-A2, HLA-DRB1*11 (HLA-DR5 subtype) and HLA-
DRB1*08. JIA with positive rheumatoid factor (RF) is con-
sidered to be an equivalent of adult RF positive rheuma-
toid arthritis (RA) and like for adults is associated with
HLA-DR4. JIA type with negative RF is heterogeneous and
HLA associations are not so distinct as of other types.
Arthritis with enthesitis is associated with the presence of
HLA B27 allele [8]. Arthritis with enthesitis is a disease,
similar to spondyloarthropathies, but children, unlike
adults for whom the dominating symptom is inflammatory
backache, have their extra-axial joints involved in the pro-
cess - mainly lower extremities. For some patients with
arthritis with enthesitis the disease may advance and affect
sacroiliac joints and spine, and within 5 -10 years it may
develop AS clinical symptoms, however usually it takes
many years before sacroilitis and spondylitis get visible
radiologically [9]. It is known that in children HLA B27
alleles are connected with other JIA types, like oligo- and
polyarthritis, but especially with arthritis with enthesitis
and juvenile spondyloarthropathies [10-12].
Human leukocyte antigen HLA (Human Leukocyte
Antigen) B27 or allele HLA B27 is a cell-surface protein
and genetically the main cell compatibility complex
MHC class I molecule [13]. It possesses several proven
specific functions within immune system, but many
functions stay still unclear. One of the main functions of
this molecule is ability to present peptide antigens,
which result from intracellular degradation of proteins,
to other cells of the immune system, mainly to CD8 T
cells. Recent researches revealed the importance of this
molecule in the function of natural killer cells [14].
It is found out, that HLA B27 is not a single allele, but
it represents a highly homologous HLA B alleles family,
called types of alleles and denoted as HLA B*2701,
B*2702 etc. The number of alleles discovered is con-
stantly growing and up to now there are already 31
types: from B*2701 to B*2727, and moreover - allele
*2705 has five subtypes - *270502-270507 [15]. These
alleles differ from each other by one or several amino
acids in peptide binding site, and by their diverse race/
ethnic prevalence in the world population [16].
In Latvia according to data of the Latvian Rheumatic
Disease Patient Registry, in 2006 the JIA prevalence was
861 patients, among which 119 carried positive HLA B27
allele. Each of HLA B27 positive patients may have a dif-
ferent type of disease (polyarhritis, oligoarthritis, arthritis
with enthesitis), as well as a different degree of disease
activity. Usually the presence of this allele determines the
primary choice of therapy - treatment with Sulphasala-
zine (SS). SS is one of the first anti-rheumatic drugs and
the first drug that has been developed specially for RA
treatment, today SS is considered as DMARDS group
drug. In 1930ies Prof. Nanna Svartz, a rheumatologist at
the Karolinska Institute in Stockholm, advanced a postu-
late that RA is a disease of bacterial aetiology and it
should be treated with preparations of sulphonamide
group, which at that were already available. Prof. Svartz
noticed that in RA treatment, combining the antibiotic
sulphanilamide with the salicylates of anti-inflammatory
therapy did not bring any solid benefit, and produced sig-
nificant gastrointestinal side effects. Svartz was of an opi-
nion, that these two medical products when combined
chemically could at least decrease the gastrointestinal
intolerance and asked Swedish Pharmaceutical enterprise
Pharmacia in Upsala to merge chemically these two pre-
parations. Thus linking sulphapyiridine to 5-aminosali-
cyilic acid, a new medication was derived with the name
Sulphasalazine [17]. First reports on using SS in JIA ther-
apy appeared in 1986, when Özdogan in his research
work published the results on 18 JIA patients [18]. Since
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eral other studies [19-29].
In rheumatology efficacy of the therapy can be judged
in 3- 6 months after the beginning of the treatment. Van
Rossum et al in double-blind placebo-controlled trial
showed, that SS is a safe and effective medication both
managing the symptoms of arthritis, and improving the
inflammation data in patients with oligo- and polyarticu-
lar JIA, though one third of the patients developed intol-
erance [19,28]. SS is indicated also for patients with HLA
B27 associated spondiloarthropathies [24]. Exact
mechanism of SS performance is still not fully clear and
is under continuous research. It is known, that SS has
several anti-inflammation and immunomodulating
effects: inhibits cell chemotaxis in inflammation, separa-
tion of mononuclear cell cytokines, proliferation and acti-
vation of lymphocytes, formation of osteoclasts,
angiogenesis, activity of folate-dependent enzymes. Pri-
mary side-effects which may occur during SS therapy are
gastrointestinal problems (anorexia, nausea, diarrhea),
rashes, headache and increase of liver transaminases.
The clinical praxis shows that, SS therapy efficacy may
vary with different JIA patients: in one part of patients
SS takes a good control over the progress of arthritis, as
well as decreases laboratory figures of inflammation, in
other part of patients the SS efficacy is insufficient and
it is necessary to combine or change the medication.
Patients with insufficient therapeutic effect to SS, receive
instead a different basic drug - Methotrexate (MTX). In
severe cases of disease, combined therapy of MTX and
SS is prescribed. If such conventional therapy however
proves to be ineffective, the patient receives treatment
with glycocorticosteroids or biological medication, like,
TNF alpha receptor blocker - Etanercept.
Unfortunately, so far there is no scientifically
grounded explanation found for such differences. There
are no studies done yet in children rheumatology
regarding MHC and choice of JIA treatment. Probably
because the research of different JIA subtypes and asso-
ciated genes are still in progress and the ILAR classifica-
tion continues its improvement [30]. Another fields of
medicine already carry out active pharmacogenetic
research in treatment of different diseases, as well there
is already the practical use in patients therapy , for
example in HIV patients[31,32], hepatitis C in field of
hepatology [33], in treatment of multiple sclerosis in the
field of neurology [34,35]. There are few articles in
rheumatology on individual HLA allele association with
choice of therapeutical drugs, e.g. HLA B27 positive
heel enthesitis treatment with Adalilumab [36] or HLA
DR3 positive rheumatoid arthritis treatment and side
effects with gold therapy [37].
Taking into account, that JIA is a heterogeneous
group of diseases, the therapy tactics for different types
of the disease may differ. If it were possible already in
early stage of the disease to predict, for which HLA B27
positive patients the SS therapy would be effective, and
for which patients the therapy would not achieve the
desired efficacy, then patients could be prescribed the
most appropriate and effective medication from the very
beginning, to get early control of the disease, because, as
studies of long-term observations show, suppressing the
activity of the disease already at the early stage of the
disease, has a favourable influence on the further pro-
gress of the disease, and the positive therapeutic effect
can persist in a longer period of time [19].
In Latvia for children with JIA no genetic studies have
been performed on the incidence of allele types
HLAB27, as well as their possible connection with dif-
ferent JIA types and choice of therapy.
Hereby, hypothesis is raised, that there might exist
connection between allele types HLA B27, JIA types and
patient’s reaction to anti-rheumatic therapy.
Materials and methods
Subjects
The study design was compound - prospective and retro-
spective, where during the period from year 2006 - 2009,
in the study were included 56 children at the age from 3
to 18 years. All patients had HLA B27 positive JIA.
The JIA diagnosis and type of the disease was con-
firmed according to ILAR criteria. Efficacy of the treat-
ment was evaluated and measured for every 3 month
according to ACR Pediatric 30 a clinical response and
improvement criteria [20,21]. The ACR Pediatric 30
use the following 6 basic a clinical response and
improvement criteria: physician global assessment of
overall disease activity; parent or patient global assess-
ment of overall well-being; functional ability; number
of joints with active arthritis; number of joints with
limited range of motion and erythrocyte sedimentation
r a t e .T oc o n s i d e rat h e r a p e u t i cr e s p o n s ei nJ I A
patients, improvement has to be at least in 3 of 6 cri-
teria for 30% [21].
HLA class I HLAB27 allele was determined by poly-
merase chain reaction (PCR). There was determined 31
type of HLA B27 (from B*2701-B*2727; *2705 type 5
sybtypes - *270502-270507).
DNA isolation and HLA B27 typing by PCR
The DNA samples were taken starting with peripheral
blood cells using the “salting-out” method [38,39]. The
genetic amplification was performed through PCR
[38,39]. MHC classes I antigens subtype identifying by
PCR-SSP method that apply MHC class I allele: HLA-
B*2701 to HLA-B *2727 specificity detection. These
DNA samples were processed by SSP DYNAL Invitrogen
Corporation USA.
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out” technique. HLA-B loci were typed according to the
DNA typing method described by Bunce et al [40]. This
polymerase chain reaction (PCR) technique uses
sequence-specific primer (SSP) reactions to simulta-
neously identify alleles of the class I locus in an allele-
specific or group-specific manner.
To identify class I alleles each PCR reaction consisted
of in final concentration, 0.02 _g DNA, 0.42 units Taq
DNA polymerase, 1_L of 10X Buffer IV, 3.4 mM
MgCl2, 250_M of each dNTP, 0.54 _L glycerol, 0.01 _L
1 0 0m g / m LC r e s o lR e d ,a n d5_ Lo ft h ea l l e l e - s p e c i f i c
and control primer mixes at a concentration of 1-4 _M
each. The PCR reaction mix was plated out into 96-well
plates, and amplifications were carried. The cycling
parameters used were as follows: 96°C for 1 minute, fol-
lowed by 14 cycles of 96°C for 30 seconds, 65°C for 50
seconds, and 72°C for 20 seconds, followed by 25 cycles
of 96°C for 30 seconds, 62°C for 50 seconds, 72°C for 20
seconds, followed by 72°C for 4 minutes. The PCR pro-
ducts were electrophoresed in a 1.5% agarose gel for
approximately 35 minutes at 150 V in 0.5 Tris-borate-
EDTA (TBE) and visualized using UV illumination.
Statistical
The HLA-B*2701 to HLA-B *2727 allele frequencies in
patients with juvenile idiopathic arthritis and control
subjects were compared using the chi-square (c
2)t e s t
and gene frequency (gf). The P value and odds ratio
(OR) were calculated using EPI INFO software, version
06, with 95% confidence intervals and Fisher exact cor-
rection for small numbers [41].
Results
The study included 56 white children - 25 boys (45%)
and 31 girls (55%). Patient mean age was 12.34 ± 3.32
years (from 3 to 16 years). At the onset of disease 7% of
patients were under 7 years and over 7 years -93%.
In the process of evaluation for received therapy we
found 24 patients (43%) to be effective with MTX, 18
patients (32%) with SS. 7 patients (12.5%) required com-
bined SS with MTX therapy, but in 7 patients (12.5%)
due to ineffective standard therapy treatment with biolo-
gical drug Etanercept with MTX were started.
Division of HLA B27 positive JIA patient in groups
According to ILAR criteria all JIA patients were divided
in 3 groups: 23% of oligoarthritis, 33%- polyarthritis ser-
onegative and 44%- enthesitis related arthritis.
Division of HLA B27 positive JIA patient by sex
In 96% of HLA B27 positive JIA boys was diagnosed
enthesitis related arthritis and in 4% - polyarthritis.
There were no oligoarthritis in boys diagnosed.
In 58% of HLA B27 positive JIA girls was diagnosed
polyarthritis, in 39% oligoarthritis, but enthesitis related
arthritis in 3%.
Distribution of HLA B 27 allele types in homogeneous JIA
patient groups
In JIA patients by typing HLA class I B27 with PCR
*B2705 type (OR = 2.01, p < 0.02) was found more fre-
quently (55%) in enthesitis related arthritis group,
*B2710 (OR = 3.0, p < 0.04) in oligoarthritis group
(11%) and *B2717 (OR = 3.0, p < 0.05) in polyarthritis
patient group (9%). Other HLA B27 types were found
respectively less (Table 1).
Distribution of HLA B 27 allele types by sex
By analyzing the frequency of HLA B27 allele types
between male and female, the most frequently (68%)
found type in boys was *B2705, but *B2703 type in 12%
of cases and just in boys.
In girls the most frequently found HLA B27 allele type
was *B2705 - in 45% of all female patients, but *2704 type
in 3% of cases and *B2715 in 6% of cases and was diag-
nosed just in girls.
Association of HLA B 27 allele types with ANA
In HLA B27 positive patients positive ANA was found
in 18 cases (32%) with *2715 type (OR = 2.18, p < 0.05),
but significantly less positive ANA cases in patients with
*2702 (OR = 0.69, p < 0.01) type and *2717 (OR = 0.21,
p < 0.00) type (Table 2).
Occurrence of HLA B 27 allele types in homogeneous JIA
therapy groups
In evaluation the efficacy of treatment in JIA groups and
HLA B27 types, the data showed statisticcaly significant
therapeutic effect of MTX (OR = 1.13, p < 0.03) and MTX
with SS (OR = 2.02, p < 0.05) in *2705 type positive
patients, but MTX with Etanercept combined therapy was
necessary for *2703 type (OR = 2.94, p < 0.02) (Table 3).
Therapy with SS, which is recommended start therapy
in HLA B27 positive JIA patients, did not show signifi-
cantly positive efficacy of treatment in any of HLAB27
allele type.
Discussion
T h ep r e s e n ts t u d yi nL a t v i ai st h ef i r s to ft h i sk i n d
regarding analysis of HLA B27 allele types, DMARDS
therapy and their significance in children with JIA.
Genetic studies are of significant importance, in order
to comprehend the etiology and pathogenesis of JIA, as
well will directly address the question of heterogeneity
by analysis of the correlation between different JIA typs
genomic variants and clinical responses to therapy. Dif-
ferent studies have shown that there exists association
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al having studied HLA data in 680 JIA patients, came to
a conclusion, that there exists a HLA specific age of
years regarding onset of the disease, and it is unique for
every JIA type [42]. In 1973 it was suggested that there
was association between incidence of AS and HLA B27.
Since then onwards, a great amount of scientific
research has been performed on HLA B27, but no
explicit knowledge of the role of this antigen in the dis-
ease pathogenesis, has been found up till now [6]. To
date it has been found that HLA B27 is a heterogeneous
allele group.
According to the published data, the most common
HLA B27 allele types are B*2705 (in representatives of
Caucasian race and American Indians), B*2704 (Asiatic),
and HLA-B*2702 (Mediterranean population) [43]. All
these alleles are linked also with AS. It has been found
out that there are also other HLA B27 allele types asso-
ciated with AS, like HLA-B*2701, B*2703, B*2707,
B*2708, B*2710, B*2713, B*2714, B*2715, B*2719, and
B*2725 [23]. The incidence of the largest part of these
other alleles is small and rare, and their possible linkage
with the disease, is not yet found out completely. It has
been suggested, that there are 2 alleles, which do not
have any connection with AS progression - HLA-
B*2706, prevailing in Southeast Asia, and HLA-B*2709,
which is found to be a prevailing allele on the Italian
island Sardinia [44]. The two above mentioned alleles
have not been detected in JIA patients in Latvia.
It is known, that HLA B27 allele has its role also in the
paediatric population. According to the published data,
76% of children with arthritis and enthesitis have HLA
B27 positive [45]. This type of JIA is associated with
enthesitis and arthritis, and affects mainly boys after 6
years of age. In neighbour country Estonia, 28.6% of chil-
dren with JIA, had positive HLA B27 [46]. There are 13,
8% B27 positive JIA patients in Latvia. Bersntson et al
prospective studies with 305 JIA patients from three Nor-
dic countries (Sweden, Norway and Denmark) concluded
that HLA B27 is of great significance for boys with JIA.
For HLA B27 positive boys, unlike patients with negative
Table 1 Association between JIA type and HLAB27 allele type
JIA subgroups Arthritis and enthesitis n = 25, OR/
c
2/p
Oligoarthritis n = 12, OR/
c
2/p
Polyarthritis, n= 19, OR/
c
2/p
All children with JIA n = 56
, gf
HLA B*27
subtypes
*2702 0.04 - 0.16 0.07
*2703 0.08 - - 0.05
*2704 - 0.08 - 0.03
*2705 2.01/5,25/0.02 0.39/0,021** 0.39/0,021** 0.56
*2710 0.04 3.0/0.710/0.04 0.11 0.03
*2715 - 0.08 0.05 0.07
*2717 0.04 - 3.0/0.81/0,05 0.07
*2728 0.08 - 0.11 0.10
* HLA B*27 subtypes.
Group JIA - children with juvenile idiopathic arthritis.
** type protective statistically significant association for patients all JIA subjects.
Results are only shown for those alleles where there was evidence for a difference between JIA subgroups.
Bold-face type highlights statistically significant associations for patients all JIA subjects;
gf (allele frequency), P (probability), OR (odds ratio) and x
2 values of OR are reported only for significant associations ( P < 0.05).
n = number of patients.
Table 2 Association between ANA and HLAB 27allele
type
All children with JIA, n = 56
HLA B*27
subtypes
ANA positive n =
18
ANA negative n
=3 8
OR p <
*2702 1 3 0.69** 0.01
*2703 1 2 1.06 0.09
*2704 1 - nd -
*2705 11 20 1.41 0.59
*2710 1 1 0.39 0.01
*2715 11 2.18 0.05
*2717 - 4 0.21** 0.00
*2728 2 3 1.46 0.28
* HLA B*27 subtypes.
JIA - children with juvenile idiopathic arthritis.
** type protective statistically significant association for patients all JIA
subjects;
Results are only shown for those alleles where there was evidence for a
difference between JIA subgroups.
Bold-face type highlights statistically significant associations for patients all JIA
subjects;
gf (allele frequency), P (probability), OR (odds ratio) and x
2 values of OR are
reported only for significant associations ( P < 0.05).
n - number of patients.
nd - not defined
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the first three years of affection, with involvement of
lower extremity joints [47].
According to the data of our studies in Latvia, boys
and girls, primarily after 7 years of age, equally often
develop HLA B27 positive JIA, the most frequent JIA
type being arthritis with enthesitis (44%). However, ana-
lysing the JIA type incidence among boys and girls, it is
the boys after 7 years of age, who most often develop
arthritis and enthesitis (96%), whereas girls - polyarthri-
tis (58%) and oligoarthritis (39%). Also other published
research data confirm these correlations [5].
Totally it was detected, that in Latvia in children with
HLA B27 positive, JIA is associated with 8 HLA B27
allele types: *2702, *2703, *2704, *2705, *2710, *2715,
*2717, *2728, however, credibly the most frequent types
are HLA B*2705,*2710 and *2717. Analyzing the data
about relationship between JIA type and HLA B27 allele
type, credibly positive association has arthritis with
enthesitis with *2705 type (OR = 2.01, p < 0.02), polyar-
thritis with *2717 (OR = 3.0, p < 0.05) and oligoarthritis
with *2710 type (OR = 3.0, p < 0.04). These findings
once again show, that according to the published data,
JIA is a heterogeneous disease and genetic predisposi-
tion varies with different JIA types [17].
There exists HLA B27 association with acute anterior
uveitis (AAU) [48]. In our study uveitis was diagnosed in 3
patients and all three patients had *2705 type. AAU
involves serious complications like glaucoma, cataract,
ocular hypotony, formation of synechia, and consequently
may lead to visual impairment and deterioration in the
q u a l i t yo fl i f e[ 4 9 ] .F r e q u e n t l yA A Up r o g r e s sm a yb e
asymptomatic, for that reason a timely diagnostics and
treatment are of utmost importance in prevention of com-
plications. The number of patients with uveitis involved in
this study is insufficient to be able to develop any recom-
mendations, but we believe that patients with *B2705 type
need more frequent slit lamp examinations at oculist’s.
JIA studies provide convincing evidence that there is
genetic component and much of the genetic work, done
in last three decades, related HLA genes’ research, e.g.
HLA class I B27 allele association with different JIA
types and consequences [30,37]. Probably different JIA
types and variable expression of drug receptors, metabo-
lizing enzymes, and transporter systems have been
linked to genetic polymorphism and individual differ-
ences in efficacy of DMARDS group drugs [35].
Today MTX is considered to be basic medication
from among DMARDs in JIA therapy [50], and during
our study, when treating with MTX, therapeutic effect
was reached in 43% of JIA patients. But guidelines of
JIA therapy recommend, that treatment of HLAB27
positive JIA cases should be started with SS, but evaluat-
ing the efficacy of treatment according ACR Pediatric30
criteria, our findings revealed, that with SS therapeutic
effect was reached only in 32% cases, and still 12.5% of
patients needed SS combination with MTX, but for
55.5% of patients it was necessary to remove SS, and
therapeutic effect was reached only by MTX or MTX in
combination with Etanercept.
Table 3 Association between effective treatment and HLAB27 allele type
Treatment
Groups
SS+ MTX n = 7, OR/
c
2/p
MTX n = 24, OR/
c
2/p
SS n = 18, OR/
c
2/p
MTX+ Enbrel n = 7, OR/
c
2/p
All children with JIA n = 56 ,
gf
HLA B*27
subtypes
*2702 - 0.57/0.13/0.01** 2.26/1.75/0.65 - 0.07
*2703 - 0.08 - 2.94/0.50/0.02 0.05
*2704 - - 3.24/0.38/0.22 - 0.02
*2705 2.02/0.16/0.05 1.13/0.54/0.03 0.05 0.6/0.35/0.02** 0.55
*2710 0.29 0.08 0.49/0.35/0.05** 0.14 0.11
*2715 - 0.04 3.24/0.38/0.22 - 0.04
*2717 - 0.08 0.06 0.14 0.07
*2728 - 0.08 0.11 0.14 0.10
* HLA B*27 subtypes.
JIA - children with juvenile idiopathic arthritis.
** type protective statistically significant association for patients all JIA subjects.
Results are only shown for those alleles where there was evidence for a difference between JIA subgroups.
Group SS +MTX indicates combination therapy with Sulfasalazine and Methotrexate
Group MTX indicates therapy with Methotrexate;
Group MTX+Enbrel indicate combination therapy with Methotrexate and Enbrel;
Bold-face type highlights statistically significant associations for patients all JIA subjects;
gf (allele frequency), P (probability), OR (odds ratio) and x
2 values of OR are reported only for significant associations ( P < 0.05).
n = number of patients.
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neous JIA type and HLA B27 allele type groups, it was
found, that boys after age of 7, who most frequently
developed arthritis and enthesitis and who credibly most
often had *2705 type after 3 months of insufficient effi-
cacy of treatment with SS, produced therapeutic efficacy
with MTX and SS with MTX.
Analyzing separately the girl group we found out that
also for girls, who in 3% cases developed arthritis and
enthesitis and where also *2705 was present, credible
therapeutic effect could be reached with SS with MTX,
but for girls, in cases with association of *2710, SS does
not produce any therapeutic effect. Likewise in cases of
polyarthritis which girls had most frequently and asso-
ciation with *2717 was found, credibly effective
DMARDs therapy was not proved.
Patients with *2703 need combined therapy - biologi-
cal with MTX.
The obtained data of the efficacy evaluation suggest
that the conventional primary JIA therapy with SS does
not produce the desired therapeutic effect, and in order
to keep control of the disease and to improve the quality
of life for children, MTX should be chosen as primary
therapy. However, in order to apply the most appropriate
therapy from the early onset of the disease, it would be
really necessary to determine the HLA B27 allele type,
and aimfully launch a therapy with MTX, SS, MTX with
SS or MTX with Enbrel. Moreover, to make the obtained
data more exact and credible, it would be necessary to
survey all HLAB27 positive JIA patients in Latvia.
Analyzing ANA connection with HLA B27 allele types
and therapy efficacy in homogeneous JIA type groups,
no credibility were found, so we may assume, that ANA
most probably indicates the prognosis of the disease and
not disease severity, like it was already proved in rheu-
matology with other autoimmune diseases, when, for
instance, autoantibody - positive RF indicates to a prog-
nosis of worsening and faster progressing course of dis-
ease in a case of seropositve JIA [10].
The study shows again, that JIA is a group of hetero-
geneous diseases with diverse genetic basis. It explains
also the fact, that patients with different JIA types have
varied reaction to the therapy. It would be very useful to
continue genetic studies on JIA and HLAB27 allele
types, because possibly, nuzzling of the genetic material
is a way to finding the most suitable therapy, which, in
its turn, is a key to more favourable prognosis of the
disease.
Conclusions
Our findings indicate a trend to have HLAB 27 positive
JIA in children over 7 years of age and the most com-
mon type is enthesitis related arthritis. Girls tend to
have HLA B27 positive oligo- and polyarthritis, where
boys most often have enthesitis related arthritis.
I nH L AB 2 7p o s i t i v eJ I Ap a t i e n t st h em o s te f f e c t i v e
disease modifying antirheumatic drug is MTX - in 43%
of study patients, SS - 32%, but SS with MTX - 12.5%
study patients. Combined biologic therapy with MTX
and Etanercept was necessary for 12.5% of patients.
There are 8 different HLA B27 alleles in JIA patients
in Latvia: *2702, *2703, *2704, *2705, *2710, *2715,
*2717, *2728, and the most common significantly are
*2705, *2710, *2717.
HLA B*2705 allele is significantly often found to
enthesitis related arthritis group, *2710 in oligoarthritis
group and *2717 - in polyarthritis patient group.
The data showed statisticcaly significant efficacy of
treatment of MTX and MTX with SS in *2705 allele
type patients, but MTX with Etanercept was effective in
*2703 allele type patients.
Standard treatment approach with SS proves to be
satisfactory in the half of HLA B27 positive JIA patients.
To improve children’s quality of life achieving rapid dis-
ease control, the first line treatment in HLA B27 posi-
tive patients should be MTX. In order to start with the
most appropriate drug: MTX, SS, MTX with SS or
MTX with Enbrel, it is necessary to determine HLAB 27
type at the onset of disease. But in order to assert the
above mentioned data, more extensive studies are
needed, including all HLA B27 positive JIA patients in
Latvia which would lead to the development of good
practice guidelines.
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